Ask a research question about Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies:
name: Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies
creation_date: "2026-04-23T00:00:00Z"
updated_date: "2026-05-10T14:23:45Z"
category: Neurological Disorder
parents:
- Autoimmune Disorder
- Demyelinating Disease
disease_term:
preferred_term: neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
term:
id: MONDO:0035663
label: neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
pathophysiology:
- name: AQP4-Reactive B Cell Autoantibody Production
description: >-
Peripheral B-lineage cells generate pathogenic AQP4-IgG, creating the
circulating autoantibody substrate for astrocyte-targeted NMOSD attacks.
genes:
- preferred_term: AQP4
term:
id: hgnc:637
label: AQP4
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: plasma cell
term:
id: CL:0000786
label: plasma cell
- preferred_term: plasmablast
term:
id: CL:0000980
label: plasmablast
evidence:
- reference: PMID:31495497
reference_title: "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing
the risk of attacks and disability in NMOSD.
explanation: >-
This supports B-lineage cells as a therapeutically relevant upstream
driver of NMOSD attacks.
- reference: PMID:36933107
reference_title: "Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
which is designed to suppress autoantibody production by blocking the
interleukin-6 (IL-6) receptor
explanation: >-
This directly supports autoantibody production as an upstream
therapeutic target in AQP4-positive NMOSD.
downstream:
- target: Blood-Brain Barrier Disruption
description: Circulating AQP4-IgG requires CNS access through barrier-vulnerable sites or BBB disruption.
- target: Anti-AQP4 Binding to Perivascular Astrocytes
description: AQP4-IgG production provides the antibody substrate for astrocyte binding.
- name: Blood-Brain Barrier Disruption
description: >-
Early blood-brain barrier dysfunction permits circulating AQP4
autoantibodies to enter the central nervous system and reach vulnerable
perivascular astrocyte endfeet.
locations:
- preferred_term: blood brain barrier
term:
id: UBERON:0000120
label: blood brain barrier
biological_processes:
- preferred_term: regulation of blood-brain barrier permeability
term:
id: GO:1905603
label: regulation of blood-brain barrier permeability
modifier: ABNORMAL
evidence:
- reference: DOI:10.3390/ijms251910625
reference_title: Blood–Brain Barrier Disruption in Neuroimmunological Disease
supports: SUPPORT
snippet: >-
At the onset of NMOSD, increased permeability of the BBB causes the
entry of circulating AQP4 autoantibodies into the central nervous
system (CNS).
explanation: >-
Directly supports barrier disruption as the enabling step for
pathogenic anti-AQP4 antibody access to the CNS.
downstream:
- target: Anti-AQP4 Binding to Perivascular Astrocytes
description: Barrier leak enables circulating anti-AQP4 antibodies to engage astrocytic targets.
- name: Anti-AQP4 Binding to Perivascular Astrocytes
description: >-
Pathogenic NMO-IgG binds extracellular AQP4 on perivascular astrocytic
endfeet, with higher-order orthogonal arrays of particles increasing
antibody avidity and pathogenicity.
genes:
- preferred_term: AQP4
term:
id: hgnc:637
label: AQP4
cell_types:
- preferred_term: astrocyte
term:
id: CL:0000127
label: astrocyte
locations:
- preferred_term: blood brain barrier
term:
id: UBERON:0000120
label: blood brain barrier
evidence:
- reference: PMID:35454180
reference_title: "Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System."
supports: SUPPORT
snippet: >-
In NMOSD, the autoantibody (NMO-IgG) binds to the extracellular loops
of AQP4 as expressed in perivascular astrocytic end-feet and disrupts
astrocytes in a complement-dependent manner.
explanation: >-
Directly supports antibody binding to perivascular astrocytic AQP4 as
the initiating lesion in AQP4-positive NMOSD.
downstream:
- target: Classical Complement Activation on Astrocytes
description: Antibody-coated astrocytes become substrates for complement-mediated injury.
- target: Secondary Demyelination and Neuronal Injury
description: Astrocyte dysfunction disrupts homeostatic support for oligodendrocytes and neurons.
- name: Classical Complement Activation on Astrocytes
description: >-
Anti-AQP4 immune complexes activate the classical complement pathway,
generating terminal complement-mediated astrocyte injury and driving the
complement-sensitive relapse biology of AQP4-positive disease.
genes:
- preferred_term: C3
term:
id: hgnc:1318
label: C3
- preferred_term: C5
term:
id: hgnc:1331
label: C5
biological_processes:
- preferred_term: complement activation, classical pathway
term:
id: GO:0006958
label: complement activation, classical pathway
evidence:
- reference: PMID:31050279
reference_title: Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
supports: SUPPORT
snippet: >-
At least two thirds of cases are associated with aquaporin-4
antibodies (AQP4-IgG) and complement-mediated damage to the central
nervous system.
explanation: >-
This trial abstract directly frames AQP4-positive NMOSD as a
complement-mediated CNS disease.
downstream:
- target: Complement-Dependent Th17 Cytokine Amplification
description: Complement effector activity amplifies downstream cytokine and immune-cell responses.
- target: Secondary Demyelination and Neuronal Injury
description: Complement-mediated astrocyte loss propagates tissue-destructive downstream injury.
- name: Complement-Dependent Th17 Cytokine Amplification
description: >-
AQP4 immune complexes stimulate complement-dependent IL-6 and IL-17A
release, reinforcing a Th17-skewed inflammatory program and sustaining
relapse-prone neuroinflammation.
genes:
- preferred_term: IL6
term:
id: hgnc:6018
label: IL6
cell_types:
- preferred_term: T helper 17 cell
term:
id: CL:0000899
label: T-helper 17 cell
biological_processes:
- preferred_term: interleukin-6-mediated signaling pathway
term:
id: GO:0070102
label: interleukin-6-mediated signaling pathway
- preferred_term: T-helper 17 cell differentiation
term:
id: GO:0072539
label: T-helper 17 cell differentiation
evidence:
- reference: DOI:10.1038/s41598-024-53661-5
reference_title: Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Co-stimulation of PBMCs with AQP4-IgG/AQP4 immunocomplex and
complement prompts a Th17-biased response consistent with the
inflammatory paradigm observed in NMOSD.
explanation: >-
Directly supports complement-dependent IL-6/IL-17 immune amplification
downstream of AQP4 immune-complex formation.
downstream:
- target: Granulocyte-Rich Neuroinflammation
description: Th17-skewed cytokine signaling promotes further innate immune recruitment and lesion propagation.
- name: Granulocyte-Rich Neuroinflammation
description: >-
AQP4-IgG-based models reproduce granulocyte and macrophage infiltration,
capturing the neutrophil- and eosinophil-rich inflammatory pattern that
distinguishes AQP4-positive NMOSD lesions from multiple sclerosis.
cell_types:
- preferred_term: neutrophil
term:
id: CL:0000775
label: neutrophil
- preferred_term: eosinophil
term:
id: CL:0000771
label: eosinophil
- preferred_term: macrophage
term:
id: CL:0000235
label: macrophage
evidence:
- reference: DOI:10.4103/nrr.nrr-d-23-01325
reference_title: "Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These experimental models have successfully simulated many
pathological features of neuromyelitis optica spectrum disorders,
such as aquaporin-4 loss, astrocytopathy, granulocyte and macrophage
infiltration, complement activation, demyelination, and neuronal loss;
explanation: >-
This directly supports the granulocyte- and macrophage-rich lesion
ecology characteristic of AQP4-IgG-positive NMOSD.
downstream:
- target: Optic Neuritis
description: Inflammatory astrocytopathy and demyelination frequently affect the optic nerves.
- target: Longitudinally Extensive Transverse Myelitis
description: Granulocyte-rich inflammatory lesions in the spinal cord produce LETM.
- target: Area Postrema Syndrome
description: Barrier-vulnerable brainstem regions such as the area postrema are frequent symptomatic targets.
- name: Secondary Demyelination and Neuronal Injury
description: >-
Astrocyte-targeted injury leads secondarily to demyelination and neuronal
loss rather than primary oligodendrocyte autoimmunity, explaining the
destructive opticospinal phenotype of anti-AQP4 disease.
cell_types:
- preferred_term: oligodendrocyte
term:
id: CL:0000128
label: oligodendrocyte
biological_processes:
- preferred_term: myelination
term:
id: GO:0042552
label: myelination
modifier: DYSREGULATED
cellular_components:
- preferred_term: myelin sheath
term:
id: GO:0043209
label: myelin sheath
evidence:
- reference: DOI:10.4103/nrr.nrr-d-23-01325
reference_title: "Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These experimental models have successfully simulated many
pathological features of neuromyelitis optica spectrum disorders,
such as aquaporin-4 loss, astrocytopathy, granulocyte and macrophage
infiltration, complement activation, demyelination, and neuronal loss;
explanation: >-
Supports the downstream sequence from astrocytopathy to demyelination
and neuronal loss in AQP4-positive NMOSD.
downstream:
- target: Optic Neuritis
description: Secondary demyelinating injury in the optic pathways drives visual attacks.
- target: Longitudinally Extensive Transverse Myelitis
description: Destructive demyelination in the spinal cord produces LETM and severe myelopathic disability.
phenotypes:
- name: Optic Neuritis
description: >-
Acute, often severe optic nerve inflammation causing visual loss and pain,
frequently with bilateral or highly disabling attacks in AQP4-positive disease.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: optic neuritis
term:
id: HP:0100653
label: Optic neuritis
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The core clinical characteristics required for patients with NMOSD
with AQP4-IgG include clinical syndromes or MRI findings related to
optic nerve, spinal cord, area postrema, other brainstem,
diencephalic, or cerebral presentations.
explanation: >-
Optic nerve involvement is a core diagnostic manifestation of
AQP4-positive NMOSD.
- name: Longitudinally Extensive Transverse Myelitis
description: >-
Long spinal cord lesions spanning three or more vertebral segments are a
hallmark attack pattern in anti-AQP4 NMOSD and often drive severe motor,
sensory, and sphincter deficits.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: longitudinally extensive transverse myelitis
term:
id: HP:0012486
label: Myelitis
spatial_extent: EXTENSIVE
notes: >-
HPO lacks a dedicated LETM term, so HP:0012486 is used together with an
EXTENSIVE spatial qualifier.
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The core clinical characteristics required for patients with NMOSD
with AQP4-IgG include clinical syndromes or MRI findings related to
optic nerve, spinal cord, area postrema
explanation: >-
This directly supports spinal cord involvement as a core AQP4-positive
NMOSD manifestation.
- name: Area Postrema Syndrome
description: >-
Intractable nausea, vomiting, and hiccups caused by lesions in the area
postrema, a barrier-vulnerable circumventricular region that is highly
characteristic of AQP4-positive NMOSD.
frequency: FREQUENT
phenotype_term:
preferred_term: nausea and vomiting
term:
id: HP:0002017
label: Nausea and vomiting
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The core clinical characteristics required for patients with NMOSD
with AQP4-IgG include clinical syndromes or MRI findings related to
optic nerve, spinal cord, area postrema
explanation: >-
Area postrema syndrome is a core clinical feature in the AQP4-positive
diagnostic framework.
- name: Intractable Hiccups
description: >-
Intractable hiccups are a frequent component of area postrema syndrome in
AQP4-IgG-positive NMOSD.
frequency: FREQUENT
phenotype_term:
preferred_term: intractable hiccups
term:
id: HP:0100247
label: Recurrent singultus
evidence:
- reference: PMID:30258024
reference_title: "Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
and hiccups (102, 65%) lasted a median of 14 days (2-365).
explanation: >-
This directly supports hiccups as a frequent APS symptom in
AQP4-IgG-positive NMOSD.
- name: Acute Brainstem Syndrome
description: >-
Brainstem attacks can produce diplopia, dysphagia, and other focal
cranial-nerve or long-tract symptoms in anti-AQP4 NMOSD.
frequency: OCCASIONAL
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The core clinical characteristics required for patients with NMOSD
with AQP4-IgG include clinical syndromes or MRI findings related to
optic nerve, spinal cord, area postrema, other brainstem,
diencephalic, or cerebral presentations.
explanation: >-
Other brainstem presentations are explicitly included among the core
AQP4-IgG-positive NMOSD clinical characteristics.
- name: Diencephalic Syndrome
description: >-
Diencephalic involvement can produce hypothalamic or endocrine symptoms
in a subset of patients with anti-AQP4 disease.
frequency: OCCASIONAL
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The core clinical characteristics required for patients with NMOSD
with AQP4-IgG include clinical syndromes or MRI findings related to
optic nerve, spinal cord, area postrema, other brainstem,
diencephalic, or cerebral presentations.
explanation: >-
Diencephalic presentations are explicitly recognized within the
AQP4-IgG-positive NMOSD diagnostic criteria.
diagnosis:
- name: Serum AQP4-IgG testing
description: >-
Detection of serum AQP4-IgG defines the seropositive subtype and is the
central laboratory procedure distinguishing this disorder from other
inflammatory demyelinating diseases.
results: >-
A positive serum AQP4-IgG assay supports the diagnosis of anti-AQP4
NMOSD and anchors serostatus-specific interpretation of core syndromes.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: MAXO:0000003
label: diagnostic procedure
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The new nomenclature defines the unifying term NMO spectrum disorders
(NMOSD), which is stratified further by serologic testing (NMOSD with
or without AQP4-IgG).
explanation: >-
This directly supports serologic AQP4-IgG testing as the basis for
subtype-defining diagnostic stratification.
- reference: PMID:35454180
reference_title: "Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System."
supports: SUPPORT
snippet: >-
NMO-IgG is an excellent marker for distinguishing the disease from
other inflammatory demyelinating diseases, such as multiple sclerosis.
explanation: >-
This directly supports AQP4 autoantibody testing as a differentiating
diagnostic assay.
- name: MRI of optic pathways, spinal cord, and brainstem
description: >-
MRI is used to document lesion localization in the optic nerves, spinal
cord, area postrema, brainstem, and diencephalon within the AQP4-IgG
diagnostic framework.
results: >-
MRI patterns involving the optic nerve, spinal cord, area postrema,
brainstem, diencephalon, or cerebrum support diagnosis in the correct
serologic context.
diagnosis_term:
preferred_term: magnetic resonance imaging procedure
term:
id: MAXO:0000424
label: magnetic resonance imaging procedure
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
The core clinical characteristics required for patients with NMOSD
with AQP4-IgG include clinical syndromes or MRI findings related to
optic nerve, spinal cord, area postrema, other brainstem,
diencephalic, or cerebral presentations.
explanation: >-
This directly supports MRI as a central diagnostic modality for
lesion-pattern confirmation in AQP4-positive NMOSD.
differential_diagnoses:
- name: MOG antibody-associated disease
description: >-
MOGAD can satisfy NMO/NMOSD criteria but differs from anti-AQP4 disease in
sex distribution, imaging patterns, and overall clinical outcome.
distinguishing_features:
- MOG-antibody-positive disease shows more conus and deep gray matter involvement on MRI.
- Anti-AQP4-positive patients relapse more often and tend to have less favorable outcomes.
evidence:
- reference: PMID:24425068
reference_title: "Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study."
supports: SUPPORT
snippet: >-
Despite the fact that patients with MOG-Abs can fulfill the
diagnostic criteria for NMO, there are differences when compared with
those with AQP4-Abs.
explanation: >-
Directly supports MOGAD as a key differential diagnosis that can mimic
anti-AQP4 NMOSD while remaining clinically distinct.
- name: Multiple sclerosis
description: >-
Multiple sclerosis is the classic inflammatory demyelinating differential,
but anti-AQP4-seropositive NMOSD is a distinct astrocytopathic syndrome
with different serology and lesion biology.
distinguishing_features:
- Anti-AQP4 seropositivity and area postrema/LETM patterns favor NMOSD over multiple sclerosis.
- NMOSD is driven by astrocyte-directed autoimmunity rather than primary MS-type demyelinating pathology.
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
snippet: >-
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct
from multiple sclerosis (MS) that is associated with serum
aquaporin-4 immunoglobulin G antibodies (AQP4-IgG).
explanation: >-
This directly supports multiple sclerosis as the major diagnostic
alternative from which AQP4-positive NMOSD must be separated.
genetic:
- name: HLA-DRB1*03:01
association: Associated
notes: >-
HLA class II association supports an adaptive immune predisposition but is
not itself the disease-defining lesion in anti-AQP4 NMOSD.
evidence:
- reference: PMID:33420337
reference_title: "Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis."
supports: SUPPORT
snippet: >-
The main HLA association with Neuromyelitis Optica was the DRB1*03:01
allele in Western populations and with the DPB1*05:01 allele in Asia.
explanation: >-
Supports a reproducible HLA association in NMOSD while keeping the
primary disease model centered on anti-AQP4 autoimmunity.
treatments:
- name: Eculizumab
description: >-
Anti-C5 complement blockade directly targets the complement-dependent
astrocytopathic mechanism of anti-AQP4 NMOSD and reduces relapse risk.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: eculizumab
term:
id: NCIT:C48386
label: Eculizumab
target_mechanisms:
- target: Classical Complement Activation on Astrocytes
treatment_effect: INHIBITS
description: >-
C5 blockade prevents terminal complement-mediated astrocyte injury in
AQP4-IgG-positive disease.
evidence:
- reference: PMID:31050279
reference_title: Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
supports: SUPPORT
snippet: >-
At least two thirds of cases are associated with aquaporin-4
antibodies (AQP4-IgG) and complement-mediated damage to the
central nervous system.
explanation: >-
This directly supports complement blockade as a mechanism-matched
therapy in AQP4-positive NMOSD.
evidence:
- reference: PMID:31050279
reference_title: Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
supports: SUPPORT
snippet: >-
Adjudicated relapses occurred in 3 of 96 patients (3%) in the
eculizumab group and 20 of 47 (43%) in the placebo group
explanation: >-
The PREVENT trial demonstrates major relapse reduction in
AQP4-IgG-positive NMOSD.
- name: Inebilizumab
description: >-
Anti-CD19 B-lineage depletion reduces the cellular source of pathogenic
AQP4 autoantibody production and lowers attack risk.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: inebilizumab
term:
id: NCIT:C88283
label: Inebilizumab
target_mechanisms:
- target: AQP4-Reactive B Cell Autoantibody Production
treatment_effect: INHIBITS
description: >-
B-lineage depletion lowers the upstream anti-AQP4 autoantibody burden
that drives astrocyte-targeted attacks.
evidence:
- reference: PMID:31495497
reference_title: "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial."
supports: SUPPORT
snippet: >-
21 (12%) of 174 participants receiving inebilizumab had an attack
versus 22 (39%) of 56 participants receiving placebo
explanation: >-
The N-MOmentum trial supports inebilizumab as effective relapse
prevention in anti-AQP4 NMOSD.
- name: Satralizumab
description: >-
IL-6 receptor blockade interferes with the cytokine-amplification loop
that supports plasmablast survival and Th17-skewed inflammation in
anti-AQP4 disease.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: satralizumab
term:
id: NCIT:C152307
label: Satralizumab
target_mechanisms:
- target: Complement-Dependent Th17 Cytokine Amplification
treatment_effect: INHIBITS
description: >-
IL-6 receptor blockade counters the inflammatory cytokine program
downstream of AQP4 immune-complex signaling.
- target: AQP4-Reactive B Cell Autoantibody Production
treatment_effect: INHIBITS
description: >-
IL-6 receptor blockade can also reduce plasmablast survival and
upstream AQP4-IgG production.
evidence:
- reference: PMID:36933107
reference_title: "Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder."
supports: SUPPORT
snippet: >-
Satralizumab (Enspryng®) is a monoclonal antibody that blocks the
interleukin-6 (IL-6) receptor and is approved for the treatment of
neuromyelitis optica spectrum disorder (NMOSD) in patients who are
aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.
explanation: >-
Directly supports IL-6R blockade as a mechanism-matched approved
therapy for the anti-AQP4 subtype.
clinical_trials:
- name: NCT01892345
description: >-
PREVENT randomized trial of eculizumab in AQP4-IgG-positive NMOSD.
target_phenotypes:
- preferred_term: optic neuritis
term:
id: HP:0100653
label: Optic neuritis
- preferred_term: myelitis
term:
id: HP:0012486
label: Myelitis
evidence:
- reference: PMID:31050279
reference_title: Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
supports: SUPPORT
snippet: >-
Among patients with AQP4-IgG-positive NMOSD, those who received
eculizumab had a significantly lower risk of relapse than those who
received placebo.
explanation: >-
This directly supports PREVENT as a pivotal interventional trial in
anti-AQP4 NMOSD.
- name: NCT02200770
description: >-
Randomized placebo-controlled inebilizumab trial in anti-AQP4-positive
NMOSD.
target_phenotypes:
- preferred_term: optic neuritis
term:
id: HP:0100653
label: Optic neuritis
- preferred_term: myelitis
term:
id: HP:0012486
label: Myelitis
evidence:
- reference: PMID:31495497
reference_title: "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial."
supports: SUPPORT
snippet: >-
Compared with placebo, inebilizumab reduced the risk of an NMOSD
attack.
explanation: >-
Supports N-MOmentum as a pivotal disease-modifying trial for
anti-AQP4-positive NMOSD.
datasets: []
references:
- reference: PMID:26092914
title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
findings:
- statement: '2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729.'
supporting_text: '2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729.'
evidence:
- reference: PMID:26092914
reference_title: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
supports: SUPPORT
evidence_source: OTHER
snippet: '2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729.'
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
- reference: PMID:30258024
title: "Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD."
findings: []
- reference: PMID:24425068
title: "Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study."
findings: []
- reference: PMID:31050279
title: Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
findings:
- statement: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord.
supporting_text: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord.
evidence:
- reference: PMID:31050279
reference_title: Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
- reference: PMID:31495497
title: "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial."
findings: []
- reference: PMID:33420337
title: "Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis."
findings: []
- reference: PMID:35454180
title: "Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System."
findings: []
- reference: PMID:36933107
title: "Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder."
findings: []
- reference: DOI:10.1038/s41598-024-53661-5
title: Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders
findings:
- statement: 'Proinflammatory cytokines, such as (IL: interleukin) IL-6 and IL-17A, and complement fixation are critical in the immunopathogenesis of neuromyelitis optica spectrum disorders (NMOSD).'
supporting_text: 'Proinflammatory cytokines, such as (IL: interleukin) IL-6 and IL-17A, and complement fixation are critical in the immunopathogenesis of neuromyelitis optica spectrum disorders (NMOSD).'
evidence:
- reference: DOI:10.1038/s41598-024-53661-5
reference_title: Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: 'Proinflammatory cytokines, such as (IL: interleukin) IL-6 and IL-17A, and complement fixation are critical in the immunopathogenesis of neuromyelitis optica spectrum disorders (NMOSD).'
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
- reference: DOI:10.3390/ijms251910625
title: Blood–Brain Barrier Disruption in Neuroimmunological Disease
findings: []
- reference: DOI:10.4103/nrr.nrr-d-23-01325
title: "Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis"
findings:
- statement: Neuromyelitis optica spectrum disorders are neuroinflammatory demyelinating disorders that lead to permanent visual loss and motor dysfunction.
supporting_text: Neuromyelitis optica spectrum disorders are neuroinflammatory demyelinating disorders that lead to permanent visual loss and motor dysfunction.
evidence:
- reference: DOI:10.4103/nrr.nrr-d-23-01325
reference_title: 'Aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis'
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Neuromyelitis optica spectrum disorders are neuroinflammatory demyelinating disorders that lead to permanent visual loss and motor dysfunction.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
- reference: DOI:10.1007/s00415-024-12452-8
title: 'Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis'
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Aquaporin-4 (AQP4) antibody-associated neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated inflammatory disease of the central nervous system.
supporting_text: Aquaporin-4 (AQP4) antibody-associated neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated inflammatory disease of the central nervous system.
evidence:
- reference: DOI:10.1007/s00415-024-12452-8
reference_title: 'Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis'
supports: SUPPORT
evidence_source: OTHER
snippet: Aquaporin-4 (AQP4) antibody-associated neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated inflammatory disease of the central nervous system.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.1007/s11940-021-00667-3
title: New Therapeutic Landscape in Neuromyelitis Optica
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: New Therapeutic Landscape in Neuromyelitis Optica
supporting_text: New Therapeutic Landscape in Neuromyelitis Optica
- reference: DOI:10.1007/s40120-024-00597-7
title: Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
supporting_text: Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
- reference: DOI:10.1007/s40265-018-1039-7
title: 'Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options'
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: 'Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options'
supporting_text: 'Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options'
- reference: DOI:10.1016/j.msard.2024.105522
title: Epidemiology of aquaporin-4-IgG-positive NMOSD in Sardinia
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Epidemiology of aquaporin-4-IgG-positive NMOSD in Sardinia
supporting_text: Epidemiology of aquaporin-4-IgG-positive NMOSD in Sardinia
- reference: DOI:10.1016/j.neurol.2016.03.003
title: 'Neuromyelitis optica spectrum disorder (NMOSD): A new concept'
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: 'Neuromyelitis optica spectrum disorder (NMOSD): A new concept'
supporting_text: 'Neuromyelitis optica spectrum disorder (NMOSD): A new concept'
- reference: DOI:10.1056/nejmoa1901747
title: Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
supporting_text: Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- reference: DOI:10.1080/14712598.2020.1749259
title: Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders
supporting_text: Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders
- reference: DOI:10.1093/brain/awad373
title: Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder
supporting_text: Neuromyelitis optica spectrum disorder (NMOSD) is a CNS autoimmune inflammatory disease mediated by T helper 17 (Th17) and antibody responses to the water channel protein, aquaporin 4 (AQP4), and associated with astrocytopathy, demyelination and axonal loss.
evidence:
- reference: DOI:10.1093/brain/awad373
reference_title: Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Neuromyelitis optica spectrum disorder (NMOSD) is a CNS autoimmune inflammatory disease mediated by T helper 17 (Th17) and antibody responses to the water channel protein, aquaporin 4 (AQP4), and associated with astrocytopathy, demyelination and axonal loss.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.1097/wno.0000000000000396
title: 'Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica'
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Neuromyelitis optica (NMO) is an autoimmune demyelinating disorder of the central nervous system (CNS) with predilection for the optic nerves and spinal cord.
supporting_text: Neuromyelitis optica (NMO) is an autoimmune demyelinating disorder of the central nervous system (CNS) with predilection for the optic nerves and spinal cord.
evidence:
- reference: DOI:10.1097/wno.0000000000000396
reference_title: 'Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica'
supports: SUPPORT
evidence_source: OTHER
snippet: Neuromyelitis optica (NMO) is an autoimmune demyelinating disorder of the central nervous system (CNS) with predilection for the optic nerves and spinal cord.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.1186/s12974-021-02249-1
title: 'Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies'
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM).
supporting_text: Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM).
evidence:
- reference: DOI:10.1186/s12974-021-02249-1
reference_title: 'Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM).
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.1212/nxi.0000000000000134
title: Update on biomarkers in neuromyelitis optica
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Update on biomarkers in neuromyelitis optica
supporting_text: Update on biomarkers in neuromyelitis optica
- reference: DOI:10.1212/nxi.0000000000000837
title: Treatment and outcome of aquaporin-4 antibody–positive NMOSD
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Treatment and outcome of aquaporin-4 antibody–positive NMOSD
supporting_text: Treatment and outcome of aquaporin-4 antibody–positive NMOSD
- reference: DOI:10.1212/wnl.0000000000002655
title: Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder
supporting_text: Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder
- reference: DOI:10.1212/wnl.0000000000209888
title: Eculizumab Use in Neuromyelitis Optica Spectrum Disorders
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Eculizumab Use in Neuromyelitis Optica Spectrum Disorders
supporting_text: Eculizumab Use in Neuromyelitis Optica Spectrum Disorders
- reference: DOI:10.3389/fneur.2024.1332890
title: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
supporting_text: To assess the pharmacokinetics and pharmacodynamics of the long-acting terminal complement 5 (C5) inhibitor ravulizumab in adults with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the phase 3, open-label CHAMPION-NMOSD trial (NCT04201262).MethodsPatients aged 18 years or older received a weight-based intravenous loading dose of ravulizumab (2,400–3,000 mg) on day 1, followed by weight-based maintenance doses (3,000–3,600 mg) on day 15 and once every 8 weeks thereafter.
evidence:
- reference: DOI:10.3389/fneur.2024.1332890
reference_title: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: To assess the pharmacokinetics and pharmacodynamics of the long-acting terminal complement 5 (C5) inhibitor ravulizumab in adults with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the phase 3, open-label CHAMPION-NMOSD trial (NCT04201262).MethodsPatients aged 18 years or older received a weight-based intravenous loading dose of ravulizumab (2,400–3,000 mg) on day 1, followed by weight-based maintenance doses (3,000–3,600 mg) on day 15 and once every 8 weeks thereafter.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.3390/ijms17030273
title: The Immunology of Neuromyelitis Optica—Current Knowledge, Clinical Implications, Controversies and Future Perspectives
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Neuromyelitis optica (NMO) is an autoimmune, demyelinating disorder of the central nervous system (CNS) with typical clinical manifestations of optic neuritis and acute transverse myelitis attacks.
supporting_text: Neuromyelitis optica (NMO) is an autoimmune, demyelinating disorder of the central nervous system (CNS) with typical clinical manifestations of optic neuritis and acute transverse myelitis attacks.
evidence:
- reference: DOI:10.3390/ijms17030273
reference_title: The Immunology of Neuromyelitis Optica—Current Knowledge, Clinical Implications, Controversies and Future Perspectives
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Neuromyelitis optica (NMO) is an autoimmune, demyelinating disorder of the central nervous system (CNS) with typical clinical manifestations of optic neuritis and acute transverse myelitis attacks.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.3390/ijms22168638
title: Treatment of Neuromyelitis Optica Spectrum Disorders
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system (CNS) inflammatory disorder that can lead to serious disability and mortality.
supporting_text: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system (CNS) inflammatory disorder that can lead to serious disability and mortality.
evidence:
- reference: DOI:10.3390/ijms22168638
reference_title: Treatment of Neuromyelitis Optica Spectrum Disorders
supports: SUPPORT
evidence_source: OTHER
snippet: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system (CNS) inflammatory disorder that can lead to serious disability and mortality.
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
- reference: DOI:10.3390/ijms25158169
title: Humanized-Aquaporin-4-Expressing Rat Created by Gene-Editing Technology and Its Use to Clarify the Pathology of Neuromyelitis Optica Spectrum Disorder
found_in:
- Neuromyelitis_Optica_Spectrum_Disorder_with_Anti-AQP4_Antibodies-deep-research-falcon.md
findings:
- statement: Conventional rodent neuromyelitis optica spectrum disorder (NMOSD) models using patient-derived immunoglobulin G (IgG) are potentially affected by the differences between the human and rodent aquaporin-4 (AQP4) extracellular domains (ECDs).
supporting_text: Conventional rodent neuromyelitis optica spectrum disorder (NMOSD) models using patient-derived immunoglobulin G (IgG) are potentially affected by the differences between the human and rodent aquaporin-4 (AQP4) extracellular domains (ECDs).
evidence:
- reference: DOI:10.3390/ijms25158169
reference_title: Humanized-Aquaporin-4-Expressing Rat Created by Gene-Editing Technology and Its Use to Clarify the Pathology of Neuromyelitis Optica Spectrum Disorder
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Conventional rodent neuromyelitis optica spectrum disorder (NMOSD) models using patient-derived immunoglobulin G (IgG) are potentially affected by the differences between the human and rodent aquaporin-4 (AQP4) extracellular domains (ECDs).
explanation: Deep research cited this publication as relevant literature for Neuromyelitis Optica Spectrum Disorder with Anti-AQP4 Antibodies.
NMOSD with anti‑AQP4 antibodies is an autoimmune inflammatory CNS disorder distinct from multiple sclerosis, unified under the term neuromyelitis optica spectrum disorders (NMOSD) and stratified by AQP4‑IgG serostatus (AQP4‑IgG positive vs negative/unknown). (wingerchuk2015internationalconsensusdiagnostic pages 1-2, wingerchuk2015internationalconsensusdiagnostic pages 3-3)
Core concept: In AQP4‑IgG+ disease, pathogenic antibodies target the astrocyte water channel aquaporin‑4 (AQP4), producing an astrocytopathy with secondary demyelination and neuroaxonal injury. (contentti2021neuromyelitisopticaspectrum pages 1-2, collongues2019pharmacotherapyforneuromyelitis pages 1-2)
The 2015 International Panel for NMO Diagnosis (IPND) created two categories: 1) NMOSD with AQP4‑IgG 2) NMOSD without AQP4‑IgG (or unknown) (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 11-12)
Visual evidence: the IPND criteria table is available as a cropped image from the original consensus paper. (wingerchuk2015internationalconsensusdiagnostic media 83817c93)
Autoantibody-mediated astrocytopathy: AQP4‑IgG binds AQP4 at astrocyte endfeet, triggers classical complement activation and inflammatory injury; astrocyte loss precedes secondary demyelination/neuronal injury. (contentti2021neuromyelitisopticaspectrum pages 1-2, collongues2019pharmacotherapyforneuromyelitis pages 1-2)
Sex: Strong female predominance is consistent across cohorts and meta-analysis (female:male ~8.9 overall). (arnett2024sexratioand pages 1-2, sechi2024epidemiologyofaquaporin4iggpositive pages 8-12)
Coexisting autoimmunity: Coexisting systemic autoimmune diseases are common; in Sardinia 52% had concomitant autoimmune disorders (autoimmune thyroiditis most frequent). (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12, sechi2024epidemiologyofaquaporin4iggpositive pages 34-37)
Environmental factors (suggested): Proposed factors include infections, smoking, and vitamin D deficiency, based on epidemiologic discussion; high-quality causal estimates were not identified in the current evidence set. (sechi2024epidemiologyofaquaporin4iggpositive pages 34-37)
No single causal gene defines AQP4‑IgG+ NMOSD. Reported susceptibility loci/haplotypes include HLA‑DPB1, HLA‑DRB1*03:01, immune regulatory variants (e.g., PTPN22 PD‑1.3A allele, CD226 Gly307Ser) and possible protective signal at CYP7A1 G/G; HLA‑DRB1*1501 (MS risk) is not associated with NMO. (melamed2015updateonbiomarkers pages 4-5, contentti2021neuromyelitisopticaspectrum pages 2-4)
No robust protective factors or formal gene–environment interaction studies were retrieved in the current evidence set. (Gap)
For AQP4‑IgG+ NMOSD, ≥1 of the following core clinical characteristics is sufficient (with AQP4‑IgG positivity and exclusion of alternative diagnoses): 1) Optic neuritis 2) Acute myelitis 3) Area postrema syndrome (hiccups or nausea/vomiting) 4) Acute brainstem syndrome 5) Diencephalic syndrome (e.g., symptomatic narcolepsy) with typical features 6) Symptomatic cerebral syndrome with NMOSD-typical lesions (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 11-12)
AQP4‑IgG+ cohort phenotype frequencies (Korea cohort evaluating 2015 criteria): * Acute myelitis occurred in 190/226 (84%) (disease course) (hyun2016evaluationofthe pages 4-6) * Symptomatic brain syndromes occurred in 100/252 (40%) overall, with lesion-category counts area postrema 16%, brainstem 16%, cerebral 15% (hyun2016evaluationofthe pages 4-6)
Sardinia incident AQP4‑IgG+ cases (2013–2022): * LETM 68% * Optic neuritis 16% * Brainstem syndromes 6% * Encephalitis 3% * Combinations 6% (including area postrema syndromes) (sechi2024epidemiologyofaquaporin4iggpositive pages 8-12)
NMOSD is generally relapsing: 80–90% relapsing course; after first attack 60% relapse within 1 year and 90% within 3 years (older but widely cited synthesis). (jasiakzatonska2016theimmunologyof pages 3-6)
QoL and fatigue are recognized as burdensome symptoms in NMOSD, but disease‑specific quantitative QoL metrics and 2023–2024 trial‑embedded QoL data were not retrieved in the current evidence set. (duchow2020currentandemerging pages 1-5)
NMOSD with AQP4‑IgG is not a monogenic disorder; AQP4 is the antigenic target, not typically mutated. (contentti2021neuromyelitisopticaspectrum pages 1-2)
AQP4 is enriched at astrocyte endfeet and forms supramolecular orthogonal arrays of particles (OAPs), with M23 favoring OAPs; OAP clustering facilitates complement activation after antibody binding. (chan2021treatmentofneuromyelitis pages 2-3, contentti2021neuromyelitisopticaspectrum pages 2-4)
No robust epigenetic or multi‑omics (transcriptomic/proteomic/metabolomic) signatures were retrieved in the current evidence set. (Gap)
1) Peripheral immune dysregulation with plasmablast expansion; IL‑6 supports plasmablast survival and AQP4‑Ab secretion. (contentti2021neuromyelitisopticaspectrum pages 2-4) 2) AQP4‑IgG enters CNS via disrupted BBB or permissive regions and binds AQP4 on astrocyte endfeet/ependymal surfaces. (contentti2021neuromyelitisopticaspectrum pages 2-4) 3) Binding triggers classical complement activation and inflammatory infiltration (neutrophils/eosinophils/macrophages), causing astrocyte injury with loss of AQP4 and GFAP, then secondary demyelination and neuronal injury. (collongues2019pharmacotherapyforneuromyelitis pages 1-2, contentti2021neuromyelitisopticaspectrum pages 1-2)
Complement-dependent Th17 cytokine release: PBMCs from treatment‑naïve AQP4‑IgG+ NMOSD patients stimulated with AQP4 immune complexes + complement produced elevated IL‑17A and IL‑6, supporting a complement‑dependent Th17‑biased peripheral inflammatory loop. (Feb 2024; https://doi.org/10.1038/s41598-024-53661-5) (nishiyama2024antiaquaporin4immunecomplex pages 1-2)
IFN‑γ axis and modeling: Decreased IFN‑γ receptor signaling and IFN‑γ depletion in AQP4 peptide‑immunized mice produced severe NMOSD‑like disease; IL‑6/Th17 activation increased, and targeting IL‑17A, IL‑6R, or B cells improved disease; a tolerance strategy (AQP4‑peptide PLGA nanoparticles) prevented/treated disease in the model. (Nov 2024; https://doi.org/10.1093/brain/awad373) (arellano2024interferonγcontrolsaquaporin4specific pages 1-2)
Primarily affects the central nervous system with lesions in: * Optic nerve/chiasm (optic neuritis) (wingerchuk2015internationalconsensusdiagnostic pages 5-6) * Spinal cord (LETM; central cord predilection) (wingerchuk2015internationalconsensusdiagnostic pages 5-6) * Dorsal medulla/area postrema (area postrema syndrome) (wingerchuk2015internationalconsensusdiagnostic pages 5-6) * Periependymal regions around the third/fourth ventricles, hypothalamus/thalamus (wingerchuk2015internationalconsensusdiagnostic pages 5-6)
Targeted cell compartment: astrocyte endfeet at the BBB and ependymal surfaces, reflecting AQP4 localization. (collongues2019pharmacotherapyforneuromyelitis pages 1-2, contentti2021neuromyelitisopticaspectrum pages 2-4)
AQP4 supramolecular organization into OAPs influences complement activation, linking membrane organization to cytotoxicity. (chan2021treatmentofneuromyelitis pages 2-3, jasiakzatonska2016theimmunologyof pages 8-10)
Meta-analysis estimate for AQP4‑IgG+ NMOSD: female:male 8.89 (95% CI 7.78–10.15); pediatric estimate 5.68; late-onset 5.48. (Jul 2024; https://doi.org/10.1007/s00415-024-12452-8) (arnett2024sexratioand pages 1-2)
No Mendelian inheritance pattern is established; susceptibility appears polygenic/immune‑regulatory. (melamed2015updateonbiomarkers pages 4-5)
For AQP4‑IgG+ NMOSD diagnosis requires: 1) At least one core clinical characteristic, 2) Positive AQP4‑IgG (best available method; CBA strongly recommended), 3) Exclusion of alternative diagnoses. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 11-12)
2015 IPND emphasizes cell‑based serum assays (microscopy/flow) as preferred, citing pooled mean sensitivity ~76.7% and very low false-positive rate (~0.1% in an MS clinic cohort), while ELISA and IIF have lower sensitivity and more false positives. (wingerchuk2015internationalconsensusdiagnostic pages 5-6)
A separate review summarizes assay performance across platforms (example: CBA ~91% sensitivity/100% specificity reported in that review). (jasiakzatonska2016theimmunologyof pages 11-14)
Red flags favoring MS include Dawson fingers/cortical lesions, typical MS brain lesion distribution, and high frequency of oligoclonal bands; MOG‑IgG should be tested in seronegative NMOSD phenotypes. (wingerchuk2015internationalconsensusdiagnostic pages 5-6, seze2016neuromyelitisopticaspectrum pages 1-2)
Relapses are the main driver of irreversible disability; severe relapses can cause blindness and paralysis. (contentti2021neuromyelitisopticaspectrum pages 2-4)
Older synthesis: after first attack 60% relapse within 1 year and 90% within 3 years; worse prognosis linked to high early relapse frequency, severe first attack, and coexisting systemic autoimmunity. (jasiakzatonska2016theimmunologyof pages 3-6)
Pediatric AQP4‑IgG+ NMOSD: non‑White ethnicity associated with shorter time to first relapse and worse EDSS at last follow‑up. (paolilo2020treatmentandoutcome pages 3-4)
Real-world eculizumab cohort (Germany/Austria, 2014–2022): 88% attack-free; median annualized attack rate decreased from 1.0 to 0; EDSS stable (median 6.0). (ringelstein2024eculizumabusein pages 1-2)
Eculizumab real-world cohort: vaccination prior to therapy was common; 19% had attacks shortly after pre‑treatment meningococcal vaccination when not on prednisone; serious infections in 13% and deaths in 10% (including meningococcal sepsis). (ringelstein2024eculizumabusein pages 1-2)
Ravulizumab achieved immediate and sustained terminal complement inhibition in CHAMPION‑NMOSD pharmacology analyses; indirect comparisons suggest strong relapse prevention versus other mechanisms. (clardy2024networkmetaanalysisof pages 1-3)
No established strategy prevents initial development of AQP4‑IgG autoimmunity. (Gap)
Early recognition using IPND criteria and high‑specificity AQP4‑IgG testing enables earlier disease-modifying therapy and avoidance of MS therapies that may worsen NMOSD. (wingerchuk2015internationalconsensusdiagnostic pages 3-3, bennett2016findingnmothe pages 3-4)
Maintenance immunotherapy to prevent relapses is the central prevention strategy; complement inhibitor use requires meningococcal vaccination and careful infection vigilance. (chan2021treatmentofneuromyelitis pages 17-19, ringelstein2024eculizumabusein pages 1-2)
Naturally occurring AQP4‑IgG NMOSD in non‑human species was not identified in the current evidence set. (Gap)
AQP4‑IgG + complement applied to in vitro/ex vivo CNS tissues or injected into CNS regions produces NMO‑like lesions (AQP4 loss, astrocytopathy, demyelination, neuron loss) but often requires BBB disruption or local delivery, limiting modeling of chronic relapsing disease. (xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 4-5, xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 8-8)
IFN‑γ depletion in AQP4_201–220‑immunized mice induces severe NMOSD‑like disease and provides a platform to test IL‑17A/IL‑6R/B‑cell targeting and tolerization nanoparticles. (arellano2024interferonγcontrolsaquaporin4specific pages 1-2)
Gene‑edited rats expressing humanized AQP4 extracellular domains enable astrocyte‑loss lesions to be induced by human AQP4‑specific antibodies, addressing species-binding limitations. (Jul 2024; https://doi.org/10.3390/ijms25158169) (namatame2024humanizedaquaporin4expressingratcreated pages 1-2)
| Item | Key quantitative result | Population/notes | Primary source (journal, year) | URL |
|---|---|---|---|---|
| 2015 IPND definition of AQP4-IgG+ NMOSD | Diagnosis requires ≥1 core clinical characteristic + positive AQP4-IgG (best available assay; cell-based assay preferred) + exclusion of alternative diagnoses. Core characteristics: optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, diencephalic syndrome, symptomatic cerebral syndrome with NMOSD-typical brain lesions (wingerchuk2015internationalconsensusdiagnostic pages 3-3, wingerchuk2015internationalconsensusdiagnostic pages 1-2, wingerchuk2015internationalconsensusdiagnostic pages 5-6) | AQP4-IgG status stratifies NMOSD into seropositive vs seronegative/unknown categories; seronegative cases require more stringent clinico-radiologic evidence (wingerchuk2015internationalconsensusdiagnostic pages 3-3, wingerchuk2015internationalconsensusdiagnostic pages 1-2) | Wingerchuk et al., Neurology, 2015 | https://doi.org/10.1212/WNL.0000000000001729 |
| Eculizumab (PREVENT) | Adjudicated relapse in 3/96 (3%) vs 20/47 (43%) with placebo; HR 0.06 (95% CI 0.02-0.20; P<0.001). Trial ARR 0.02 vs 0.35; rate ratio 0.04 (95% CI 0.01-0.15; P<0.001) (pittock2019eculizumabinaquaporin4–positive pages 1-2) | Adults with AQP4-IgG+ NMOSD; 76% remained on background immunosuppression. Headache and URTI more common; one death from pulmonary empyema in eculizumab arm (pittock2019eculizumabinaquaporin4–positive pages 1-2) | Pittock et al., New England Journal of Medicine, 2019 | https://doi.org/10.1056/NEJMoa1900866 |
| Satralizumab add-on (SAkuraSky) | Relapse in 8/41 (20%) vs 18/42 (43%) with placebo; HR 0.38 (95% CI 0.16-0.88). In AQP4-IgG+ subgroup: 11% vs 43%; HR 0.21 (95% CI 0.06-0.75) (contentti2021neuromyelitisopticaspectrum pages 11-13) | Satralizumab added to stable immunosuppressive therapy; serious adverse events and infections did not differ between groups; pain/fatigue endpoints not significantly different (contentti2021neuromyelitisopticaspectrum pages 11-13) | Yamamura et al., New England Journal of Medicine, 2019 | https://doi.org/10.1056/NEJMoa1901747 |
| Satralizumab monotherapy (SAkuraStar) | Protocol-defined relapse in 19/63 (30%) vs 16/32 (50%) with placebo; HR 0.45 (95% CI 0.23-0.89; P=0.018) (traboulsee2020safetyandefficacy pages 1-2) | Monotherapy phase 3 trial in NMOSD; adverse-event rates 473.9 vs 495.2 per 100 patient-years (satralizumab vs placebo), with similar serious adverse events and withdrawals (traboulsee2020safetyandefficacy pages 1-2) | Traboulsee et al., The Lancet Neurology, 2020 | https://doi.org/10.1016/S1474-4422(20)30078-8 |
| Inebilizumab (N-MOmentum) | Relapse in 21/174 (12%) vs 22/56 (39%) with placebo; HR 0.27. In AQP4-IgG+ subgroup: 18/161 (11%) vs 22/52 (42%); HR 0.23. Three-month confirmed disability progression: HR 0.375 (95% CI 0.148-0.952; P=0.0390) (tugizova2021newtherapeuticlandscape pages 9-11) | Anti-CD19 B-cell depletion; serious adverse events 5% (8/174) vs 9% (5/56), transient grade 3 neutropenia 2%, infusion reactions similar; two deaths occurred in open-label period (tugizova2021newtherapeuticlandscape pages 9-11) | Cree et al., The Lancet, 2019; Marignier et al., Neurology: Neuroimmunology & Neuroinflammation, 2021 | https://doi.org/10.1016/S0140-6736(19)31817-3 |
| 2024 update: Ravulizumab (CHAMPION-NMOSD PK/PD) | In 58 treated patients, serum ravulizumab stayed above therapeutic threshold in all patients through 50 weeks; immediate and complete terminal complement inhibition (free C5 <0.5 μg/mL) achieved by end of first infusion and sustained. Trial summary notes no adjudicated on-trial relapses among ravulizumab recipients (clardy2024networkmetaanalysisof pages 1-3) | Long-acting C5 inhibitor in adults with AQP4+ NMOSD; weight-based loading then maintenance every 8 weeks (clardy2024networkmetaanalysisof pages 1-3) | Ortiz et al., Frontiers in Neurology, 2024 | https://doi.org/10.3389/fneur.2024.1332890 |
| 2024 update: Ravulizumab network meta-analysis | Compared with monotherapy alternatives, ravulizumab showed lower relapse risk vs inebilizumab HR 0.09 (95% CrI 0.02-0.57) and satralizumab HR 0.08 (95% CrI 0.01-0.55), and was comparable to eculizumab HR 0.86 (95% CrI 0.16-4.52). ARR about 98% lower vs inebilizumab/satralizumab monotherapy (clardy2024networkmetaanalysisof pages 1-3) | Bayesian network meta-analysis using PREVENT, N-MOmentum, SAkuraSky, SAkuraStar, and CHAMPION-NMOSD; indirect comparisons only, no head-to-head RCTs (clardy2024networkmetaanalysisof pages 1-3) | Clardy et al., Neurology and Therapy, 2024 | https://doi.org/10.1007/s40120-024-00597-7 |
| 2024 update: Real-world eculizumab effectiveness/safety | In 52 AQP4-IgG+ patients, 88% attack-free on eculizumab; median annualized attack rate fell from 1.0 pre-treatment to 0 (P<0.001). Serious infections in 13%, deaths in 10%; among 36 vaccinated pre-eculizumab without prednisone, 7 (19%) had attacks shortly after vaccination (ringelstein2024eculizumabusein pages 1-2) | Multicenter German/Austrian real-world cohort; disability median EDSS remained stable at 6.0 and MRI lesion activity decreased (ringelstein2024eculizumabusein pages 1-2) | Ringelstein et al., Neurology, 2024 | https://doi.org/10.1212/WNL.0000000000209888 |
Table: This table summarizes the defining 2015 diagnostic criteria for AQP4-IgG-positive NMOSD and the major relapse-prevention therapies with pivotal trial outcomes, plus key 2024 clinical updates. It is useful as a compact reference for diagnosis and current treatment evidence.
References
(wingerchuk2015internationalconsensusdiagnostic pages 3-3): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.
(pittock2019eculizumabinaquaporin4–positive pages 1-2): Sean J. Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P. Fujita, Róisín Armstrong, and Dean M. Wingerchuk. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. New England Journal of Medicine, 381:614-625, Aug 2019. URL: https://doi.org/10.1056/nejmoa1900866, doi:10.1056/nejmoa1900866. This article has 957 citations and is from a highest quality peer-reviewed journal.
(ringelstein2024eculizumabusein pages 1-2): Marius Ringelstein, Susanna Asseyer, Gero Lindenblatt, Katinka Fischer, Refik Pul, Jelena Skuljec, Lisa Revie, Katrin Giglhuber, Vivien Häußler, Michael Karenfort, Kerstin Hellwig, Friedemann Paul, Judith Bellmann-Strobl, Carolin Otto, Klemens Ruprecht, Tjalf Ziemssen, Alexander Emmer, Veit Rothhammer, Florian T. Nickel, Klemens Angstwurm, Ralf Linker, Sarah A. Laurent, Clemens Warnke, Sven Jarius, Mirjam Korporal-Kuhnke, Brigitte Wildemann, Stephanie Wolff, Maria Seipelt, Yavor Yalachkov, Nele Retzlaff, Uwe K. Zettl, Paulus S. Rommer, Markus C. Kowarik, Jonathan Wickel, Christian Geis, Martin W. Hümmert, Corinna Trebst, Makbule Senel, Ralf Gold, Luisa Klotz, Christoph Kleinschnitz, Sven G. Meuth, Orhan Aktas, Achim Berthele, and Ilya Ayzenberg. Eculizumab use in neuromyelitis optica spectrum disorders. Neurology, Nov 2024. URL: https://doi.org/10.1212/wnl.0000000000209888, doi:10.1212/wnl.0000000000209888. This article has 32 citations and is from a highest quality peer-reviewed journal.
(sechi2024epidemiologyofaquaporin4iggpositive pages 8-12): Elia Sechi, Mariangela Puci, Maria Ida Pateri, Pietro Zara, Sabrine Othmani, Stefano Sotgiu, Maria Valeria Saddi, Stefania Leoni, Giuseppe Fenu, Maurizio Melis, Giovanni Sotgiu, Paolo Solla, Eleonora Cocco, and Jessica Frau. Epidemiology of aquaporin-4-igg-positive nmosd in sardinia. Multiple Sclerosis and Related Disorders, 85:105522, May 2024. URL: https://doi.org/10.1016/j.msard.2024.105522, doi:10.1016/j.msard.2024.105522. This article has 4 citations and is from a peer-reviewed journal.
(arnett2024sexratioand pages 1-2): Simon Arnett, Sin Hong Chew, Unnah Leitner, Jyh Yung Hor, Friedemann Paul, Michael R. Yeaman, Michael Levy, Brian G. Weinshenker, Brenda L. Banwell, Kazuo Fujihara, Hesham Abboud, Irena Dujmovic Basuroski, Georgina Arrambide, Veronika E. Neubrand, Chao Quan, Esther Melamed, Jacqueline Palace, Jing Sun, Nasrin Asgari, Simon A. Broadley, Hesham Abboud, Orhan Aktas, Raed Alroughani, Ayse Altintas, Metha Apiwattannakul, Georgina Arrambide, Jagannadha Avasarala, Brenda Banwell, Terrence F. Blaschke, James Bowen, Edgar Carnero Contentti, Tanuja Chitnis, Jerome de Seze, Guillermo Delgado-Garcia, Irena Dujmovic Basuroski, Jose Flores, Kazuo Fujihara, Lorna Galleguillos, Benjamin M. Greenberg, May Han, Joachim Havla, Kerstin Hellwig, Jyh Yung Hor, Sven Jarius, Jorge Andres Jimenez, Najib Kissani, Ingo Kleiter, Marco Lana-Peixoto, M. Isabel Leite, Michael Levy, Sara Mariotto, Maureen A. Mealy, Veronika E. Neubrand, Celia Oreja-Guevara, Lekha Pandit, Sarah M. Planchon, Anne-Katrin Pröbstel, Peiqing Qian, Chao Quan, Pavle Repovic, Claire Riley, Marius Ringelstein, Juan I.Rojas, Dalia Rotstein, Klemens Ruprecht, Maria José Sá, Albert Saiz, Sara Salama, Sasitorn Siritho, Aksel Siva, Terry J. Smith, Elias S. Sotirchos, Ibis Soto de Castillo, Silvia Tenembaum, Pablo Villoslada, Barbara Willekens, Dean Wingerchuk, Bassem I. Yamout, and Michael Yeaman. Sex ratio and age of onset in aqp4 antibody-associated nmosd: a review and meta-analysis. Journal of Neurology, 271:4794-4812, Jul 2024. URL: https://doi.org/10.1007/s00415-024-12452-8, doi:10.1007/s00415-024-12452-8. This article has 39 citations and is from a domain leading peer-reviewed journal.
(nishiyama2024antiaquaporin4immunecomplex pages 1-2): Shuhei Nishiyama, Jin Myong Seok, Amy E. Wright, Itay Lotan, Takahisa Mikami, Natalia C. Drosu, Natasha Bobrowski-Khoury, Monique R. Anderson, Philippe A. Bilodeau, Patrick Schindler, Friedemann Paul, Masashi Aoki, Michael R. Yeaman, Michael Levy, Jacinta M. Behne, Megan K. Behne, Jeffrey L. Bennett, Terrence F. Blaschke, Tanuja Chitnis, Lawrence J. Cook, Michael Levy, Sarah M. Planchon, Pavle Repovic, Claire S. Riley, Terry J. Smith, Anthony Traboulsee, and Michael R. Yeaman. Anti-aquaporin-4 immune complex stimulates complement-dependent th17 cytokine release in neuromyelitis optica spectrum disorders. Scientific Reports, Feb 2024. URL: https://doi.org/10.1038/s41598-024-53661-5, doi:10.1038/s41598-024-53661-5. This article has 20 citations and is from a peer-reviewed journal.
(arellano2024interferonγcontrolsaquaporin4specific pages 1-2): Gabriel Arellano, Eileah Loda, Yanan Chen, Tobias Neef, Andrew C Cogswell, Grant Primer, Godwin Joy, Kevin Kaschke, Samantha Wills, Joseph R Podojil, Brian Popko, Roumen Balabanov, and Stephen D Miller. Interferon-γ controls aquaporin-4-specific th17 and b cells in neuromyelitis optica spectrum disorder. Brain : a journal of neurology, 147:1344-1361, Nov 2024. URL: https://doi.org/10.1093/brain/awad373, doi:10.1093/brain/awad373. This article has 26 citations.
(clardy2024networkmetaanalysisof pages 1-3): Stacey L. Clardy, Sean J. Pittock, Orhan Aktas, Jin Nakahara, Noriko Isobe, Diego Centonze, Sami Fam, Adrian Kielhorn, Jeffrey C. Yu, Jeroen Jansen, and Ina Zhang. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurology and Therapy, 13:535-549, May 2024. URL: https://doi.org/10.1007/s40120-024-00597-7, doi:10.1007/s40120-024-00597-7. This article has 24 citations and is from a domain leading peer-reviewed journal.
(wingerchuk2015internationalconsensusdiagnostic pages 1-2): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.
(contentti2021neuromyelitisopticaspectrum pages 1-2): Edgar Carnero Contentti and Jorge Correale. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, Sep 2021. URL: https://doi.org/10.1186/s12974-021-02249-1, doi:10.1186/s12974-021-02249-1. This article has 376 citations and is from a peer-reviewed journal.
(collongues2019pharmacotherapyforneuromyelitis pages 1-2): Nicolas Collongues, Estelle Ayme-Dietrich, Laurent Monassier, and Jérôme de Seze. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs, 79:125-142, Jan 2019. URL: https://doi.org/10.1007/s40265-018-1039-7, doi:10.1007/s40265-018-1039-7. This article has 73 citations and is from a domain leading peer-reviewed journal.
(wingerchuk2015internationalconsensusdiagnostic pages 5-6): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.
(bennett2016findingnmothe pages 11-12): Jeffrey L. Bennett. Finding nmo: the evolving diagnostic criteria of neuromyelitis optica. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 36 3:238-45, Sep 2016. URL: https://doi.org/10.1097/wno.0000000000000396, doi:10.1097/wno.0000000000000396. This article has 57 citations.
(wingerchuk2015internationalconsensusdiagnostic media 83817c93): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.
(sechi2024epidemiologyofaquaporin4iggpositive pages 34-37): Elia Sechi, Mariangela Puci, Maria Ida Pateri, Pietro Zara, Sabrine Othmani, Stefano Sotgiu, Maria Valeria Saddi, Stefania Leoni, Giuseppe Fenu, Maurizio Melis, Giovanni Sotgiu, Paolo Solla, Eleonora Cocco, and Jessica Frau. Epidemiology of aquaporin-4-igg-positive nmosd in sardinia. Multiple Sclerosis and Related Disorders, 85:105522, May 2024. URL: https://doi.org/10.1016/j.msard.2024.105522, doi:10.1016/j.msard.2024.105522. This article has 4 citations and is from a peer-reviewed journal.
(melamed2015updateonbiomarkers pages 4-5): Esther Melamed, Michael Levy, Patrick J. Waters, Douglas Kazutoshi Sato, Jeffrey L. Bennett, Gareth R. John, Douglas C. Hooper, Albert Saiz, Amit Bar-Or, Ho Jin Kim, Lakha Pandit, Maria Isabel Leite, Nasrin Asgari, Najib Kissani, Rogier Hintzen, Romain Marignier, Sven Jarius, John Marcelletti, Terry J. Smith, Michael R. Yeaman, May H. Han, Orhan Aktas, Metha Apiwattanakul, Brenda Banwell, Denis Bichuetti, Simon Broadley, Philippe Cabre, Tanuja Chitnis, Jerome De Seze, Kazuo Fujihara, Benjamin Greenberg, Kerstin Hellwig, Raffaele Iorio, Sven Jarius, Eric Klawiter, Ingo Kleiter, Marco Lana-Peixoto, Nakashima, Kevin O'Connor, Jacqueline Palace, Friedman Paul, Naraporn Prayoonwiwat, Klemens Ruprecht, Olaf Stuve, Thomas Tedder, Silvia Tenembaum, Juan P. Garrahan, Buenos Aires, Katja van Herle, Danielle van Pelt, Pablo Villoslada, Emmanuelle Waubant, Brian Weinshenker, Dean Wingerchuk, Jens Würfel, and Scott Zamvil. Update on biomarkers in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation, Aug 2015. URL: https://doi.org/10.1212/nxi.0000000000000134, doi:10.1212/nxi.0000000000000134. This article has 146 citations.
(contentti2021neuromyelitisopticaspectrum pages 2-4): Edgar Carnero Contentti and Jorge Correale. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, Sep 2021. URL: https://doi.org/10.1186/s12974-021-02249-1, doi:10.1186/s12974-021-02249-1. This article has 376 citations and is from a peer-reviewed journal.
(hyun2016evaluationofthe pages 4-6): Jae-Won Hyun, In Hye Jeong, AeRan Joung, Su-Hyun Kim, and Ho Jin Kim. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology, 86:1772-1779, May 2016. URL: https://doi.org/10.1212/wnl.0000000000002655, doi:10.1212/wnl.0000000000002655. This article has 99 citations and is from a highest quality peer-reviewed journal.
(jasiakzatonska2016theimmunologyof pages 3-6): Michalina Jasiak-Zatonska, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, and Wojciech Kozubski. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17:273, Mar 2016. URL: https://doi.org/10.3390/ijms17030273, doi:10.3390/ijms17030273. This article has 148 citations.
(duchow2020currentandemerging pages 1-5): Ankelien Duchow, Friedemann Paul, and Judith Bellmann-Strobl. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opinion on Biological Therapy, 20:1061-1072, Apr 2020. URL: https://doi.org/10.1080/14712598.2020.1749259, doi:10.1080/14712598.2020.1749259. This article has 25 citations and is from a peer-reviewed journal.
(chan2021treatmentofneuromyelitis pages 2-3): Koon-Ho Chan and Chi-Yan Lee. Treatment of neuromyelitis optica spectrum disorders. International Journal of Molecular Sciences, 22:8638, Aug 2021. URL: https://doi.org/10.3390/ijms22168638, doi:10.3390/ijms22168638. This article has 74 citations.
(bennett2016findingnmothe pages 3-4): Jeffrey L. Bennett. Finding nmo: the evolving diagnostic criteria of neuromyelitis optica. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 36 3:238-45, Sep 2016. URL: https://doi.org/10.1097/wno.0000000000000396, doi:10.1097/wno.0000000000000396. This article has 57 citations.
(OpenTargets Search: Neuromyelitis optica spectrum disorder): Open Targets Query (Neuromyelitis optica spectrum disorder, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(jasiakzatonska2016theimmunologyof pages 8-10): Michalina Jasiak-Zatonska, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, and Wojciech Kozubski. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17:273, Mar 2016. URL: https://doi.org/10.3390/ijms17030273, doi:10.3390/ijms17030273. This article has 148 citations.
(wingerchuk2015internationalconsensusdiagnostic pages 3-4): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.
(sechi2024epidemiologyofaquaporin4iggpositive pages 12-14): Elia Sechi, Mariangela Puci, Maria Ida Pateri, Pietro Zara, Sabrine Othmani, Stefano Sotgiu, Maria Valeria Saddi, Stefania Leoni, Giuseppe Fenu, Maurizio Melis, Giovanni Sotgiu, Paolo Solla, Eleonora Cocco, and Jessica Frau. Epidemiology of aquaporin-4-igg-positive nmosd in sardinia. Multiple Sclerosis and Related Disorders, 85:105522, May 2024. URL: https://doi.org/10.1016/j.msard.2024.105522, doi:10.1016/j.msard.2024.105522. This article has 4 citations and is from a peer-reviewed journal.
(jasiakzatonska2016theimmunologyof pages 11-14): Michalina Jasiak-Zatonska, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, and Wojciech Kozubski. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17:273, Mar 2016. URL: https://doi.org/10.3390/ijms17030273, doi:10.3390/ijms17030273. This article has 148 citations.
(wingerchuk2015internationalconsensusdiagnostic pages 4-5): Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William Carroll, Tanuja Chitnis, Jérôme de Seze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Lana-Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony L. Traboulsee, Patrick Waters, Kay E. Wellik, and Brian G. Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85:177-189, Jul 2015. URL: https://doi.org/10.1212/wnl.0000000000001729, doi:10.1212/wnl.0000000000001729. This article has 5364 citations and is from a highest quality peer-reviewed journal.
(seze2016neuromyelitisopticaspectrum pages 1-2): J. D. Seze, L. Kremer, and N. Collongues. Neuromyelitis optica spectrum disorder (nmosd): a new concept. Revue neurologique, 172 4-5:256-62, Apr 2016. URL: https://doi.org/10.1016/j.neurol.2016.03.003, doi:10.1016/j.neurol.2016.03.003. This article has 60 citations and is from a peer-reviewed journal.
(paolilo2020treatmentandoutcome pages 3-4): Renata Barbosa Paolilo, Yael Hacohen, Elise Yazbeck, Thais Armangue, Arlette Bruijstens, Christian Lechner, Samira Luisa Apostolos-Pereira, Yana Martynenko, Markus Breu, Carolina de Medeiros Rimkus, Evangeline Wassmer, Matthias Baumann, Laura Papetti, Marco Capobianco, Barbara Kornek, Kevin Rostásy, José Albino da Paz, Olga Ciccarelli, Ming Lim, Albert Saiz, Rinze Neuteboom, Romain Marignier, Cheryl Hemingway, Douglas Kazutoshi Sato, and Kumaran Deiva. Treatment and outcome of aquaporin-4 antibody–positive nmosd. Neurology Neuroimmunology & Neuroinflammation, Sep 2020. URL: https://doi.org/10.1212/nxi.0000000000000837, doi:10.1212/nxi.0000000000000837. This article has 72 citations.
(tugizova2021newtherapeuticlandscape pages 1-4): Madina Tugizova, Luka Vlahovic, Anna Tomczak, Nora Sandrine Wetzel, and May Htwe Han. New therapeutic landscape in neuromyelitis optica. Current Treatment Options in Neurology, Mar 2021. URL: https://doi.org/10.1007/s11940-021-00667-3, doi:10.1007/s11940-021-00667-3. This article has 28 citations and is from a peer-reviewed journal.
(contentti2021neuromyelitisopticaspectrum pages 11-13): Edgar Carnero Contentti and Jorge Correale. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, Sep 2021. URL: https://doi.org/10.1186/s12974-021-02249-1, doi:10.1186/s12974-021-02249-1. This article has 376 citations and is from a peer-reviewed journal.
(traboulsee2020safetyandefficacy pages 1-2): Anthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, Lech Szczechowski, Edward Fox, Svitlana Shkrobot, Takashi Yamamura, Yusuke Terada, Yuichi Kawata, Padraig Wright, Athos Gianella-Borradori, Hideki Garren, and Brian G Weinshenker. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology, 19:402-412, May 2020. URL: https://doi.org/10.1016/s1474-4422(20)30078-8, doi:10.1016/s1474-4422(20)30078-8. This article has 585 citations and is from a highest quality peer-reviewed journal.
(tugizova2021newtherapeuticlandscape pages 9-11): Madina Tugizova, Luka Vlahovic, Anna Tomczak, Nora Sandrine Wetzel, and May Htwe Han. New therapeutic landscape in neuromyelitis optica. Current Treatment Options in Neurology, Mar 2021. URL: https://doi.org/10.1007/s11940-021-00667-3, doi:10.1007/s11940-021-00667-3. This article has 28 citations and is from a peer-reviewed journal.
(chan2021treatmentofneuromyelitis pages 17-19): Koon-Ho Chan and Chi-Yan Lee. Treatment of neuromyelitis optica spectrum disorders. International Journal of Molecular Sciences, 22:8638, Aug 2021. URL: https://doi.org/10.3390/ijms22168638, doi:10.3390/ijms22168638. This article has 74 citations.
(xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 4-5): Li Xu, Huiming Xu, and Changyong Tang. Aquaporin-4-igg-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis. Neural Regeneration Research, 20:354-365, Jan 2024. URL: https://doi.org/10.4103/nrr.nrr-d-23-01325, doi:10.4103/nrr.nrr-d-23-01325. This article has 16 citations and is from a peer-reviewed journal.
(xu2025aquaporin4iggseropositiveneuromyelitisoptica pages 8-8): Li Xu, Huiming Xu, and Changyong Tang. Aquaporin-4-igg-seropositive neuromyelitis optica spectrum disorders: progress of experimental models based on disease pathogenesis. Neural Regeneration Research, 20:354-365, Jan 2024. URL: https://doi.org/10.4103/nrr.nrr-d-23-01325, doi:10.4103/nrr.nrr-d-23-01325. This article has 16 citations and is from a peer-reviewed journal.
(namatame2024humanizedaquaporin4expressingratcreated pages 1-2): Chihiro Namatame, Yoichiro Abe, Yoshiki Miyasaka, Yoshiki Takai, Yuki Matsumoto, Toshiyuki Takahashi, Tomoji Mashimo, Tatsuro Misu, Kazuo Fujihara, Masato Yasui, and Masashi Aoki. Humanized-aquaporin-4-expressing rat created by gene-editing technology and its use to clarify the pathology of neuromyelitis optica spectrum disorder. International Journal of Molecular Sciences, 25:8169, Jul 2024. URL: https://doi.org/10.3390/ijms25158169, doi:10.3390/ijms25158169. This article has 4 citations.
(levy2021newtherapiesfor pages 3-4): Michael Levy, Kazuo Fujihara, and Jacqueline Palace. New therapies for neuromyelitis optica spectrum disorder. The Lancet Neurology, 20:60-67, Jan 2021. URL: https://doi.org/10.1016/s1474-4422(20)30392-6, doi:10.1016/s1474-4422(20)30392-6. This article has 170 citations and is from a highest quality peer-reviewed journal.